Non-Sterile Liquids/Suspensions Market by Dosage Form, Application, End User & Region | Forecast 2023 to 2033

<p>The global non-sterile liquids/suspensions market held a valuation of <strong>US$ 2.6 Billion</strong> in 2022, and it is further projected to expand at a CAGR of <strong>6.5% </strong>over the forecasted years. According to a recent study by Future Market Insights, the oral dosage form is leading the market with a share of about <strong>29.5%</strong> in the year 2022, within the global market.</p><table><tbody><tr><th scope='row'>Data Points</th><td>Market Insights</td></tr><tr><th scope='row'>Market Value 2022</th><td>US$ 2.6 Billion</td></tr><tr><th scope='row'>Market Value 2033</th><td>US$ 5.2 Billion</td></tr><tr><th scope='row'>CAGR&nbsp; 2023 to 2033</th><td>6.5%</td></tr><tr><th scope='row'>Market Share of Top 5 Countries</th><td>53.0%</td></tr><tr><th scope='row'>Key Market Players</th><td>AbbVie Pharmaceutical Contract Manufacturing, Aenova Group, APPCO Pharmaceutical Corporation, Atral Pharmaceutical, Aurigene Pharmaceutical Services (Dr. Reddy&rsquo;s), Biological E. Ltd., BioPlus Life Sciences, Bora Pharmaceuticals, Cambrex Corporation, COC Farmaceutici, Contract Pharmaceuticals Limited (CPL), DPT Laboratories, Ltd., Eurofins, JGL d.d., Mikart, PharmaVision (Vizyon Holding), Pierre Fabre, TriRx Pharmaceutical Services, UI Pharmaceuticals, Wasdell Group, Aphena Pharma, and Syngene International</td></tr></tbody></table><p>Report Scope as per Non-Sterile Liquids/Suspensions Market Analysis</p><table><tbody><tr><th scope='row'>Attribute</th><td>Details</td></tr><tr><th scope='row'>Historical Data Available for</th><td>2023 to 2033</td></tr><tr><th scope='row'>Forecast Period</th><td>2012 to 2022</td></tr><tr><th scope='row'>Market Analysis</th><td>US$ Million for Value</td></tr><tr><th scope='row'>Key Regions Covered</th><td>North America, Latin America, Europe, South Asia, East Asia, Oceania, and the Middle East &amp; Africa</td></tr><tr><th scope='row'>Key Countries Covered</th><td>USA, Canada, Mexico, Brazil, Argentina, United Kingdom., Germany, Italy, Spain, France, Russia, Benelux, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, T&uuml;rkiye, GCC Countries, and South Africa</td></tr><tr><th scope='row'>Key Market Segments Covered</th><td>Dosage Form, Application, End User, and Region</td></tr><tr><th scope='row'>Key Companies Profiled</th><td><ul><li>AbbVie Pharmaceutical Contract Manufacturing</li><li>Aenova Group</li><li>APPCO Pharmaceutical Corporation</li><li>Atral Pharmaceutical</li><li>Aurigene Pharmaceutical Services (Dr. Reddy&rsquo;s)</li><li>Biological E. Ltd.</li><li>BioPlus Life Sciences</li><li>Bora Pharmaceuticals</li><li>Cambrex Corporation</li><li>COC Farmaceutici</li><li>Contract Pharmaceuticals Limited (CPL)</li><li>DPT Laboratories, Ltd.</li><li>Eurofins</li><li>JGL d.d.</li><li>Mikart</li><li>PharmaVision (Vizyon Holding)</li><li>Pierre Fabre</li><li>TriRx Pharmaceutical Services</li><li>UI Pharmaceuticals</li><li>Wasdell Group</li><li>Aphena Pharma</li><li>Syngene International</li></ul></td></tr><tr><th scope='row'>Pricing</th><td>Available upon Request</td></tr></tbody></table>

<p>全球非无菌液体/悬浮液市场在2022年达到了260亿美元的估值，并预计在未来预测期内将以6.5%的复合年增长率进一步扩张。根据未来市场洞察公司近期的研究报告，口服制剂形式的市场份额在2022年位居首位，约占全球市场的29.5%。</p><table><tbody><tr><th scope='row'>数据点</th><td>市场洞察</td></tr><tr><th scope='row'>2022年市场价值</th><td>260亿美元</td></tr><tr><th scope='row'>2033年市场价值</th><td>520亿美元</td></tr><tr><th scope='row'>2023至2033年复合年增长率</th><td>6.5%</td></tr><tr><th scope='row'>前五国市场份额</th><td>53.0%</td></tr><tr><th scope='row'>主要市场参与者</th><td>AbbVie制药合同制造、Aenova集团、APPCO制药公司、Atral制药、Aurigene制药服务（Dr. Reddy&rsquo;s）、生物E.有限公司、BioPlus生命科学、Bora制药、Cambrex公司、COC制药公司、合同制药有限公司（CPL）、DPT实验室有限公司、Eurofins、JGL d.d.、Mikart、PharmaVision（Vizyon Holding）、皮埃尔·法布、TriRx制药服务、UI制药、Wasdell集团、Aphena制药和Syngene国际</td></tr></tbody></table><p>非无菌液体/悬浮液市场分析报告范围</p><table><tbody><tr><th scope='row'>属性</th><td>详细信息</td></tr><tr><th scope='row'>历史数据可追溯至</th><td>2023至2033年</td></tr><tr><th scope='row'>预测期</th><td>2012至2022年</td></tr><tr><th scope='row'>市场分析</th><td>以百万美元计的价值</td></tr><tr><th scope='row'>主要覆盖地区</th><td>北美、拉丁美洲、欧洲、南亚、东亚、大洋洲和中东及非洲</td></tr><tr><th scope='row'>主要覆盖国家</th><td>美国、加拿大、墨西哥、巴西、阿根廷、英国、德国、意大利、西班牙、法国、俄罗斯、比荷卢经济联盟、印度、泰国、印度尼西亚、马来西亚、日本、中国、韩国、澳大利亚、新西兰、土耳其、海湾合作委员会国家、南非</td></tr><tr><th scope='row'>主要市场细分</th><td>剂型、应用、最终用户和地区</td></tr><tr><th scope='row'>主要公司简介</th><td><ul><li>AbbVie制药合同制造</li><li>Aenova集团</li><li>APPCO制药公司</li><li>Atral制药</li><li>Aurigene制药服务（Dr. Reddy&rsquo;s）</li><li>生物E.有限公司</li><li>BioPlus生命科学</li><li>Bora制药</li><li>Cambrex公司</li><li>COC制药公司</li><li>合同制药有限公司（CPL）</li><li>DPT实验室有限公司</li><li>Eurofins</li><li>JGL d.d.</li><li>Mikart</li><li>PharmaVision（Vizyon Holding）</li><li>皮埃尔·法布</li><li>TriRx制药服务</li><li>UI制药</li><li>Wasdell集团</li><li>Aphena制药</li><li>Syngene国际</li></ul></td></tr><tr><th scope='row'>定价</th><td>根据要求提供</td></tr></tbody></table>